Immunogenic Composition Combining RNA and Polypeptide Antigens
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines, particularly DNA-based and RNA-based vaccines, face challenges in efficacy and safety, including integration risks and immune response limitations, and there is a need to enhance the immune response against multiple pathogens with reduced administration burdens.
Innovation Solution
Development of immunogenic compositions combining an RNA component and a polypeptide component, where the RNA encodes one antigen and the polypeptide represents another, from different pathogens, to induce a combined immune response without the need for separate adjuvants, using self-replicating RNA molecules and specific delivery systems like liposomes or emulsions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If DNA-based vaccines are used to generate cellular immune response, then cell mediated immunity is improved, but safety risks increase due to potential integration into host genome
Solution Approach 1:
The patent extracts the beneficial immunogenic properties of DNA vaccines while removing the harmful integration risk by using RNA as the vaccine platform. RNA vaccines express antigens transiently without integrating into the host genome, thus maintaining cellular immune response generation while eliminating the safety concern about genomic integration
Solution Approach 2:
The patent employs transient RNA expression rather than permanent DNA integration. The RNA vaccine provides short-lived antigen expression that is sufficient to stimulate immune responses but does not persist in the host genome, effectively using a 'short-living' molecular platform to avoid long-term safety risks
2Reliability
If multiple separate vaccines are administered to protect against multiple pathogens, then comprehensive immune protection is achieved, but administration burden increases
Solution Approach 1:
The patent merges multiple antigen-encoding RNA sequences into a single vaccine composition that can be administered together. This combination vaccine approach consolidates multiple separate vaccinations into one administration event, reducing the number of injections and visits required while maintaining protection against multiple pathogens
Solution Approach 2:
The patent creates a multi-functional vaccine platform that can simultaneously encode multiple different antigens from various pathogens. The universal RNA vaccine system can be designed to include sequences for different viruses, bacteria, or other pathogens, providing broad-spectrum immune protection through a single administration
3Object-affected harmful factors
If RNA vaccines are used to reduce integration risks, then safety is improved, but immune response efficacy may be limited
Solution Approach 1:
The patent uses composite RNA vaccine formulations that combine multiple antigen-encoding RNA sequences with adjuvant components and delivery system elements. This composite approach enhances the immunogenicity of RNA vaccines by incorporating elements that stimulate different arms of the immune system, thereby improving overall immune response efficacy while maintaining the safety advantages of RNA
Data Source
AI summary
This invention generally relates to immunogenic compositions that comprise an RNA component and a polypeptide component. Immunogenic compositions that deliver antigens in two different forms—a first antigen from a pathogen, in RNA-coded form; and a second antigen from a different pathogen, in polypeptide form—are effective in inducing immune response to both pathogens.